Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hla-Drb and Hla-Dq Genetic Variability in Patients With Aspirin-Exacerbated Respiratory Disease Publisher Pubmed



Esmaeilzadeh H1, 2 ; Nabavi M1 ; Amirzargar AA4 ; Aryan Z3, 6 ; Arshi S1 ; Bemanian MH1 ; Fallahpour M1 ; Mortazavi N5 ; Rezaei N3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, Iran
  2. 2. Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Molecular Immunology Research Center, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Stud. Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: American Journal of Rhinology and Allergy Published:2015


Abstract

Background: Major histocompatibility complex (MHC) class II is involved in T-cell activation, cytokine secretion, and induction of immune responses. Cytokines, staphylococcus super antigens, and eosinophil activation are proposed to play important roles in aspirin-exacerbated respiratory disease (AERD). Objectives: This study is aimed at investigating the association of HLA-DRB and DQ genetic variabilities in patients with AERD. Methods: A genetic association analysis in three different groups, including 33 patients with AERD, 17 patients with aspirin-tolerant asthma (ATA), and 100 healthy controls was performed. Oral aspirin challenge (OAC) test was performed to identify aspirin hypersensitivity. Pulmonary function test (PFT) was performed for all patients. Eosinophil percentage in nasal smear and peripheral blood and serum immunoglobin (Ig)E were investigated. HLA-DRB, HLA-DQA1, and HLA-DQB1 were genotyped using polymerase chain reaction. Results: HLA-DQB1∗0302 (OR, 5.49, 95% confidence interval [CI],(2.40 -12.59)), HLA-DQA1∗0301 (OR, 2.90, 95%CI,(1.49 -5.67)), HLA-DRB4 (OR, 2.94, 95%CI,(1.61-5.36)), and HLA-DRB1∗04 (OR, 3.19, 95%CI,(1.57- 6.47)) were higher in patients with AERD compared with controls. In patients with AERD, HLA-DQB1∗0301 (OR,0.22, 95%CI,(0.09-0.54)), HLA-DQA1∗0501 (OR, 0.42, 95%CI, (0.21- 0.81)), HLA-DRB1∗11 (OR, 0.30, 95%CI,(0.12-0.73)), and HLA-DRB3 (OR, 0.38, 95%CI,(0.21- 0.70)) were significantly lower compared with healthy controls. Patients with AERD had lower frequencies of HLA-DQB1∗0301 (OR, 0.27, 95%CI,(0.08-0.86)), and HLA-DRB1∗011 (OR, 0.27, 95%CI,(0.08-0.86)) compared with ATA. Haplotypes of HLADRB1∗ 04/ DQA1∗0301/ DQB1∗0302 (OR, 4.25, 95%CI,(1.94 -9.29)) and HLA-DRB1∗07 /DQA1∗0201/ DQB1∗0201 (OR, 3.52, 95%CI,(1.54-8.06)) were higher in patients with AERD compared with controls (all p < 0.05). Conclusions: Results of this study suggest that HLA-DQB1∗0302 and HLA-DRB1∗04 and their related haplotypes are genes involved in predisposing patients to AERD, whereas HLA-DQB1∗0301 and HLA-DRB1∗011 have negative association with AERD. Copyright © 2015, OceanSide Publications, Inc., U.S.A.